Zannad, F., Greenberg, B., Cleland, J. G., Gheorghiade, M., van Veldhuisen, D. J., Mehra, M. R., . . . Mills, R. M. (2015). Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: The COMMANDER HF trial. European journal of heart failure, 17(7), 735-742. https://doi.org/10.1002/ejhf.266
Chicago Style (17th ed.) CitationZannad, Faiez, et al. "Rationale and Design of a Randomized, Double-blind, Event-driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial." European Journal of Heart Failure 17, no. 7 (2015): 735-742. https://doi.org/10.1002/ejhf.266.
MLA (9th ed.) CitationZannad, Faiez, et al. "Rationale and Design of a Randomized, Double-blind, Event-driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial." European Journal of Heart Failure, vol. 17, no. 7, 2015, pp. 735-742, https://doi.org/10.1002/ejhf.266.